$VSEE
VSEE HEALTH, INC. Stock $vsee

$vsee Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000110465923119930 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$478.4K
YoY Change
Gross Profit		$973.1K
YoY Change
Gross Profit Margin
Selling, General & Admin	$925.7K	$518.1K	$1.129M
YoY Change	-22.88%	-54.13%
% of Gross Profit		53.24%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$191.00
YoY Change
% of Gross Profit		0.02%
Operating Expenses	$925.7K	$518.1K	$1.129M
YoY Change	-22.88%	-54.13%	21702.32%
Operating Profit		-$518.1K	-$1.129M
YoY Change		-54.13%	627322.78%
Interest Expense	-$1.642M	$596.4K	$391.6K
YoY Change	-2461.59%	52.28%
% of Operating Profit
Other Income/Expense, Net	-$293.2K	$596.4K	$391.6K
YoY Change		52.28%
Pretax Income	-$2.861M	$78.29K	-$737.7K
YoY Change	153.03%	-110.61%	14141.95%
Income Tax	$0.00	-$233.7K	$83.03K
% Of Pretax Income		-298.54%
Net Earnings	-$2.861M	$78.29K	-$820.8K
YoY Change	131.68%	-109.54%	15744.77%
Net Earnings / Revenue
Basic Earnings Per Share		$0.02	-$0.05
Diluted Earnings Per Share	-$0.74	$0.02	-$54.97K
COMMON SHARES
Basic Shares Outstanding	3.584M	4.183M	14.93M
Diluted Shares Outstanding		4.183M	14.93M

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.860K	$510.00	$44.97K
YoY Change	-98.26%	-98.87%	717.64%
Cash & Equivalents	$1.863K	$507.00	$44.97K
Short-Term Investments
Other Short-Term Assets		$17.50K	$60.37K
YoY Change		-71.01%
Inventory
Prepaid Expenses		$17.50K
Receivables	$628.5K
Other Receivables
Total Short-Term Assets	$1.860K	$18.01K	$105.3K
YoY Change	-98.26%	-82.91%	1815.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.657K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.369M	$8.120M	$117.2M
YoY Change	-81.82%	-93.07%
Other Assets
YoY Change
Total Long-Term Assets	$1.369M	$8.120M	$117.2M
YoY Change	-81.82%	-93.07%	36683.88%
TOTAL ASSETS
Total Short-Term Assets	$1.860K	$18.01K	$105.3K
Total Long-Term Assets	$1.369M	$8.120M	$117.2M
Total Assets	$1.371M	$8.138M	$117.3M
YoY Change	-82.05%	-93.06%	36092.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.304M	$2.630M	$1.423M
YoY Change	75.15%	84.88%	1263.42%
Accrued Expenses	$96.36K	$31.65K
YoY Change	128.34%
Deferred Revenue	$802.5K
YoY Change
Short-Term Debt	$1.549M	$1.940M	$43.90K
YoY Change	125.55%	4320.16%	-78.04%
Long-Term Debt Due	$220.0K
YoY Change
Total Short-Term Liabilities	$7.984M	$5.022M	$1.550M
YoY Change	142.27%	224.1%	409.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.370M	$4.370M	$4.370M
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$4.370M	$4.370M	$4.370M
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.984M	$5.022M	$1.550M
Total Long-Term Liabilities	$4.370M	$4.370M	$4.370M
Total Liabilities	$12.35M	$9.392M	$5.920M
YoY Change	61.17%	58.66%	1845.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.82M	-$9.772M	-$5.587M
YoY Change	66.02%	74.9%
Common Stock	$350.00
YoY Change	0.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$10.98M	-$9.149M	-$5.587M
YoY Change
Total Liabilities & Shareholders Equity	$1.371M	$8.138M	$117.3M
YoY Change	-82.05%	-93.06%	36092.18%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	-$2.861M	$78.29K	-$820.8K
YoY Change	131.68%	-109.54%	15744.77%
Depreciation, Depletion And Amortization		$191.00
YoY Change
Cash From Operating Activities	-$321.5K	-$50.58K	-$146.2K
YoY Change	-52.46%	-65.39%	81094.44%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$6.808M	-$410.00
YoY Change	-93.82%
Cash From Investing Activities	$6.808M	-$410.00
YoY Change	-93.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-6.485M	14.50K	0.000
YoY Change	-94.07%		-100.0%
NET CHANGE
Cash From Operating Activities	-321.5K	-50.58K	-146.2K
Cash From Investing Activities	6.808M	-410.0
Cash From Financing Activities	-6.485M	14.50K	0.000
Net Change In Cash	1.360K	-36.49K	-146.2K
YoY Change	-97.81%	-75.03%	-2757.27%
FREE CASH FLOW
Cash From Operating Activities	-$321.5K	-$50.58K	-$146.2K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	dhacu	Extension Period To Consummate Business Combination ExtensionPeriodToConsummateBusinessCombination	P3M
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dhacu	Redemption Of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination	P2D
	dhacu	Redemption Period Upon Closure RedemptionPeriodUponClosure	P10D
	dhacu	Redemption Period Upon Closure RedemptionPeriodUponClosure	P10D
CY2023Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
	dei	Entity Central Index Key EntityCentralIndexKey	0001864531
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	dhacu	Maximum Extension Period To Consummate Business Combination MaximumExtensionPeriodToConsummateBusinessCombination	P9M
CY2023Q3	dhacu	Fair Value Liabilities Level2 To Level1 Transfer Amount FairValueLiabilitiesLevel2ToLevel1TransferAmount	0
CY2022Q4	dhacu	Fair Value Liabilities Level2 To Level1 Transfer Amount FairValueLiabilitiesLevel2ToLevel1TransferAmount	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
	dhacu	Extension Fee If Form S4 Registration Statement Is Filed ExtensionFeeIfFormS4RegistrationStatementIsFiled	P3M
	dhacu	Period To Regain Compliance PeriodToRegainCompliance	P10D
CY2023Q2	dhacu	Number Of Business Days During Compliance Period NumberOfBusinessDaysDuringCompliancePeriod	P10D
CY2023Q3	dhacu	Extension Period To Consummate Business Combination ExtensionPeriodToConsummateBusinessCombination	P3M
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41015
	dei	Entity Registrant Name EntityRegistrantName	DIGITAL HEALTH ACQUISITION CORP.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2970927
	dei	Entity Address Address Line1 EntityAddressAddressLine1	980 N Federal Hwy #304
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33432
	dei	City Area Code CityAreaCode	561
	dei	Local Phone Number LocalPhoneNumber	672-7068
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3583966
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	507
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106998
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	17500
CY2023Q3	us-gaap	Assets Current AssetsCurrent	18007
CY2022Q4	us-gaap	Assets Current AssetsCurrent	106998
CY2023Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	8119642
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	7527369
CY2023Q3	us-gaap	Assets Assets	8137649
CY2022Q4	us-gaap	Assets Assets	7634367
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2630100
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1886312
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	187225
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	187225
CY2023Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	138937
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	43900
CY2023Q3	dhacu	Promissory Note Related Party Classified Current PromissoryNoteRelatedPartyClassifiedCurrent	926500
CY2022Q4	dhacu	Promissory Note Related Party Classified Current PromissoryNoteRelatedPartyClassifiedCurrent	350000
CY2022Q4	dhacu	Pipe Forward Contract Derivative PipeForwardContractDerivative	170666
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5022029
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3295614
CY2023Q3	dhacu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	4370000
CY2022Q4	dhacu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	4370000
CY2023Q3	us-gaap	Liabilities Liabilities	9392029
CY2022Q4	us-gaap	Liabilities Liabilities	7665614
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	622642
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292973
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-9771586
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7719916
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-9148594
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7426596
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8137649
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7634367
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	518084
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1129361
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1668105
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2394702
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-518084
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1129361
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1668105
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2394702
CY2023Q3	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	-700506
	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	-170666
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	104413
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	391628
	us-gaap	Investment Income Interest InvestmentIncomeInterest	301860
	us-gaap	Investment Income Interest InvestmentIncomeInterest	470150
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	596371
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	391628
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	115300
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	470150
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	78287
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-737733
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1552805
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1924552
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83026
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83026
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	78287
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-820759
	us-gaap	Net Income Loss NetIncomeLoss	-1552805
	us-gaap	Net Income Loss NetIncomeLoss	-2007578
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4183123
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4183123
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14932000
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14932000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4177427
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4177427
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14932000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14932000
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7426596
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	214200
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1894642
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-9107038
CY2023Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	403953
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	263550
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-9131969
CY2023Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	94912
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	78287
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-9148594
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3334468
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-527360
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-3861828
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-659459
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-4521287
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	244634
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-820759
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-5586680
	us-gaap	Net Income Loss NetIncomeLoss	-1552805
	us-gaap	Net Income Loss NetIncomeLoss	-2007578
	dhacu	Interest Earned On Investments Held In Trust Accounts InterestEarnedOnInvestmentsHeldInTrustAccounts	301859
	dhacu	Interest Earned On Investments Held In Trust Accounts InterestEarnedOnInvestmentsHeldInTrustAccounts	470150
	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	-170666
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17500
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-397231
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	957989
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1282429
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-87037
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	83026
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-640577
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-715042
	dhacu	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	350000
	dhacu	Proceeds Of Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes ProceedsOfCashWithdrawnFromTrustAccountToPayFranchiseAndIncomeTaxes	59586
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-290414
	dhacu	Proceeds From Related Party As Advances ProceedsFromRelatedPartyAsAdvances	8000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	576500
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	250000
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	10000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	824500
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-106491
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-715042
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106998
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	760012
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	507
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44970
	us-gaap	Stock Issued1 StockIssued1	214200
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Digital Health Acquisition Corp. (the “Company” or “DHAC”) is a blank check company incorporated as a Delaware corporation on March 30, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (the “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June 9, 2022, DHAC Merger Sub I, Inc. (“Merger Sub I”), a Delaware corporation and a wholly owned subsidiary of the Company, was formed. On June 9, 2022, DHAC Merger Sub II, Inc. (“Merger Sub II”), a Texas corporation and a wholly owned subsidiary of the Company, was formed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, the Company had not commenced any significant operations. All activity for the period from inception, the date which operations commenced, through September 30, 2023 relates to the Company’s formation, the Company’s Initial Public Offering (as defined below), and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s Initial Public Offering was declared effective on November 3, 2021. On November 8, 2021, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the shares of common stock included in the Units sold, the “Public Shares”), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,500,000 Units, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described in Note 3. On October 20, 2022, in connection with the stockholders meeting to approve the extension, 10,805,877 shares of DHAC’s common stock were redeemed leaving 694,123 shares subject to redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 557,000 units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to Digital Health Sponsor LLC (the “Sponsor”), generating gross proceeds of $5,570,000, which is described in Note 4. As of November 8, 2021, the Company received $3,680,000 from the proceeds of the Private Placement and recorded $1,890,000 in subscription receivable. The Sponsor paid the subscription in full on November 12, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $6,877,164, consisting of $1,955,000 of underwriting fees, $4,370,000 of deferred underwriting fees and $552,164 of other offering costs. In addition, cash of $9,478 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on November 8, 2021, an amount of $116,725,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Trust Account is intended as a holding place for funds pending the earliest to occur of either (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company does not complete the initial Business Combination within 21 months from the closing of the Initial Public Offering (as currently extended and as may be further extended in accordance with the Amended and Restated Certificate of Incorporation) or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity; or (iii) absent an initial Business Combination within 21 months from the closing of the Initial Public Offering (as currently extended and as may be further extended in accordance with the Amended and Restated Certificate of Incorporation), the Company’s return of the funds held in the Trust Account to the Company’s public stockholders as part of the Company’s redemption of the public shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On October 20, 2022, stockholders of DHAC approved a proposal to amend DHAC’s amended and restated certificate of incorporation to (a) extend the date by which DHAC has to consummate a business combination (the “Extension”) for an additional <span style="-sec-ix-hidden:Hidden_nqL7Mm5FJUeC4NmZtoC1_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, from November 8, 2022 to February 8, 2023, (b) provide DHAC’s board of directors the ability to further extend the date by which DHAC has to consummate a business combination up to three (3) additional times for three (3) months each time, for a maximum of <span style="-sec-ix-hidden:Hidden_deztk2Cy1EO9kwH8HSs11g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nine</span></span> (9) additional months if the Sponsor pays an amount equal to $350,000 for each three-month extension (the “Extension Fee”), which amount shall be deposited in the trust account of DHAC; provided, that if as of the time of an extension DHAC has filed a Form S-4 registration statement in connection with its initial business combination, then no Extension Fee would be required in connection with such extension; provided further that for each <span style="-sec-ix-hidden:Hidden_lpSlFdkh702tlTjlgLQSKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>-month extension (if any) following such extension where no deposit into the Trust Account or other payment has been made, an Extension Fee is required, and (c) allow for DHAC to provide redemption rights to DHAC’s public stockholders in accordance with the requirements of the amended and restated certificate of incorporation without complying with the tender offer rules. In connection with such stockholder vote, an aggregate of 10,805,877 shares of DHAC’s common stock were redeemed leaving 4,156,123 shares issued and outstanding and entitled to vote as of October 20, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the net balance in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held and taxes payable on the income earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company will provide the Company’s public stockholders with the opportunity to redeem all or a portion of their common shares in connection with the initial Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) without a stockholder vote by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek stockholder approval under applicable law or stock exchange listing requirement. The public stockholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of <span style="-sec-ix-hidden:Hidden_zpz7XXINu0eT4liTCX6HlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, divided by the number of then outstanding public shares, subject to the limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The amount in the Trust Account was initially anticipated to be $10.15 per public share. On October 26, 2022, in connection with the approval of the extension, the Sponsor deposited $350,000 into the Trust Account for the first three-month extension, as such the amount in the Trust Account is anticipated to be $10.65 per public share. On February 2, 2023 the Company announced a second extension of the date by which the Company has to consummate a business combination from February 8, 2023 to May 8, 2023. On May 8, 2023 the Company announced a third extension of the date by which the Company has to consummate a business combination from May 8, 2023 to August 8, 2023 (as extended, the “Combination Period”) and deposited $350,000 into the Trust Account for such extension. The May extension is the second of three additional three-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its initial business combination. On August 1, 2023, the Company issued a press release announcing that on July 31, 2023, the Company extended the date by which the Company has to consummate a business combination from August 8, 2023 to November 8, 2023. The extension is the third of three additional three-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its initial business combination. On November 6, 2023, the Company approved four additional extensions, each by an additional <span style="-sec-ix-hidden:Hidden_AEagl7ej1EO89miqMR2-eQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> month, for an aggregate of an additional <span style="-sec-ix-hidden:Hidden_hEjWiNCR70WaY8RbjFr6Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span> months up to November 8, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">If the Company is unable to complete its initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_2ryd66z9OkagdJjv5_X9Ug;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. The shares of common stock subject to redemption are recorded at a redemption value and classified as temporary equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity.”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Sponsor, along with certain advisors, officers and directors, has entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their founder shares (as defined in Note 5) and public shares in connection with the completion of the initial Business Combination; (ii) waive their redemption rights with respect to their founder shares and public shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company have not consummated an initial Business Combination within the Combination Period or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity; (iii) waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame; and (iv) vote any founder shares held by them and any public shares purchased during or after the Initial Public Offering (including in open market and privately negotiated transactions) in favor of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company have entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.15 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.15 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor have the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that the Sponsor would be able to satisfy those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On June 15, 2022, DHAC, entered into a Business Combination agreement, by and among DHAC Merger Sub I, Inc., DHAC Merger Sub II, Inc., DHAC (together with Merger Sub I, the “Merger Subs”), VSee Lab, Inc., a Delaware corporation (“VSee”) and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc”). The Business Combination agreement and the transactions contemplated thereby (collectively, the “Business Combination”) were unanimously approved by the boards of directors of each of DHAC, VSee and iDoc on June 15, 2022. On August 9, 2022, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into the First Amended and Restated Business Combination Agreement to provide for the concurrent execution of financing documents for a PIPE consisting of convertible notes and warrants and delivery of the Cassel Salpeter’s opinion to the Board. On October 6, 2022, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into a Second Amended and Restated Business Combination Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Business Combination Agreement”) to make the consideration payable to VSee and iDoc stockholders 100% DHAC common stock and to provide for the concurrent execution of amended PIPE financing documents providing for the issuance of the shares and warrants to the PIPE investors. On July 11, 2023, each of the PIPE Investors provided notice to the Company that since a closing condition was not met, the PIPE Investors were under no obligation to close the PIPE Financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement and subject to the terms and conditions set forth therein, Merger Sub I will merge with and into VSee (the “VSee Merger”), with VSee surviving the VSee Merger as a wholly owned subsidiary of DHAC, and Merger Sub II will merge with and into iDoc (the “iDoc Merger” and, together with the VSee Merger, the “Mergers”), with iDoc surviving the iDoc Merger as a wholly owned subsidiary of DHAC. At the effective time of the Mergers (the “Effective Time”), DHAC will change its name to VSee Health, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Company received a letter (the “Letter”) from the staff (the “Staff”) at The Nasdaq Global Market (“Nasdaq Global”) notifying the Company that for the 30 consecutive trading days prior to the date of the Letter, the Company’s securities listed on the Nasdaq Global (including the Common Stock, Units and Warrants) (the “Securities”) had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities” (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of the Company’s Securities on Nasdaq Global. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s Securities on Nasdaq Global.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with Nasdaq listing rule 5810(c)(3)(C), the Company has 180 calendar days, or until September 27, 2023, to regain compliance. The Letter notes that to regain compliance, the Company’s Securities must trade at or above a level such that the Company’s MVLS closes at or above $50,000,000 for a minimum of <span style="-sec-ix-hidden:Hidden_qt8BJTndW0O8XBVyuyOG_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> consecutive business days during the compliance period, which ends September 27, 2023. The Letter further notes that if the Company is unable to satisfy the MVLS requirement prior to such date, the Company may be eligible to transfer the listing of its Securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). If the Company does not regain compliance by September 27, 2023, Nasdaq staff will provide written notice to the Company that its Securities are subject to delisting. At that time, the Company may appeal any such delisting determination to a hearings panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 23, 2023, the Company received a letter (the “Second Letter”) from the Staff. The Second Letter notifies the Company that for the 30 consecutive business days prior to the date of the Second Letter, the Company’s market value of publicly held shares (“MVPHS”) was below the $15 million required for continued listing on the Nasdaq Global and therefore, the Company no longer meets Nasdaq Listing Rule 5450(b)(3)(C) (the “MVPHS Requirement”). The Second Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq Global.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has 180 calendar days, or until November 20, 2023 (the “Compliance Date”), to regain compliance. The Second Letter notes that to regain compliance with the MVPHS Requirement, the MVPHS must equal or exceed $15 million for a minimum of <span style="-sec-ix-hidden:Hidden_O8wEF_o_Fkutgb4ii0jNtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) consecutive business days on or prior to the Compliance Date. If the Company regains compliance with the MVPHS Requirement, Nasdaq will provide the Company with written confirmation and will close the matter. The Second Letter further notes that if the Company is unable to satisfy the MVPHS requirement prior to the Compliance Date, the Company may be eligible to transfer the listing of its securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). If the Company does not regain compliance with the MVPHS Requirement by the Compliance Date, the Staff will provide written notice to the Company that its securities are subject to delisting. At that time, the Company may appeal any such delisting determination to a Nasdaq hearing’s panel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 28, 2023, the Company received a letter (the “Third Letter”) from the staff at The Nasdaq Global Market (“Nasdaq Global”) notifying the Company that the Staff has determined to delist the Company’s securities listed on Nasdaq Global (including the Common Stock, Units and Warrants) (the “Securities”) because it has not regained compliance with the Market Value of Listed Securities (“MVLS”) Standard. The market value of the Company’s listed Securities was below the $50,000,000 minimum MVLS requirement for continued listing on Nasdaq Global under Nasdaq Listing Rule 5450(b)(2)(A) (the “MLVS Rule”) and had not been at least $50,000,000 for the proceeding 30 consecutive trading days. As previously reported by the Company on its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2023, the Staff initially notified the Company on March 31, 2023 that the minimum MVLS for the Company’s Securities were below the $50,000,000 minimum MVLS requirement for the previous 30 consecutive trading days, and in accordance with the Nasdaq Listing Rules, the Company was provided 180 calendar days, or until September 27, 2023 to regain compliance with the MVLS Rule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Third Letter, on October 4, 2023, the Company requested a hearing (the “Hearing”) to appeal this determination and also applied to transfer the listing of its Securities from Nasdaq Global to the Nasdaq Capital Market (“NasdaqCM”). The Hearing is scheduled to be held on November 30, 2023 at 12:00 PM Eastern Time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On October 9, 2023, the Company received an additional letter (the “Fourth Letter”) from the staff at Nasdaq Global notifying the Company that its not meeting the 400 total shareholders requirement under the Nasdaq Listing Rule 5450(a)(2) serves as an additional basis for delisting the Company’s Securities from Nasdaq Global. The Company planned to also address the 400 total shareholder requirement at the Hearing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On October 26, 2023, the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market notified the Company in writing (the “Notice”) that its application to transfer the listing of its Securities to NasdaqCM has been approved. The Notice also stated that the Company’s Securities will be transferred to the NasdaqCM at the opening of business on October 30, 2023. On November 1, 2023, the Company received a letter from the Nasdaq Global Hearings panel that due to the Company’s transfer of its listed Securities to NasdaqCM, the Hearing on November 30, 2023 regarding non-compliance with the Nasdaq Global listing standards has been cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">As of October 30, 2023, the Company’s Securities are listed and traded on The Nasdaq Stock Market on NasdaqCM and will continue to be listed and traded on NasdaqCM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2023, the Company issued a press release announcing that on July 31, 2023, the Company extended the date by which the Company has to consummate a business combination from August 8, 2023 to November 8, 2023. The extension is the third of three additional <span style="-sec-ix-hidden:Hidden_7sN9bHnawkaILxIprwYl9w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>-month extensions permitted under the Company’s governing documents and provides the Company with additional time to complete its initial business combination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On August 17, 2023, the Company issued an amended and restated promissory note to SCS Capital Partners LLC in the aggregate principal amount of $565,000 (the “Promissory Note”), which amended and restated the promissory note issued by the Company to SCS Capital Partners LLC in February 2023. The Promissory Note bears no interest and is due and payable at the closing of the business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On September 8, 2023, DHAC held a Special Meeting and the stockholders approved the proposal to the amendment of the Company’s amended and restated certificate of incorporation (as amended, the “Charter”) to expand the methods that the Company may employ to not become subject to the “penny stock” rules of the SEC (the “Charter Amendment Proposal”) and the adjournment of the special meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Charter Amendment Proposal. On September 8, 2023, DHAC filed an amendment to its Charter pursuant to the Charter Amendment Proposal. Under the amended Charter, DHAC would be able to consummate the Business Combination even if as a result of the transactions the combined company does not have net tangible assets of at least $5,000,001 upon consummation of such business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On November 6, 2023, DHAC held its 2023 annual stockholders meeting (“2023 Annual Meeting”). At the 2023 Annual Meeting, the stockholders of DHAC approved amendments to DHAC’s Charter to extend the date by which the Company must consummate a Business Combination (as defined in the Charter) up to four (4) times, each by an additional <span style="-sec-ix-hidden:Hidden_BcXSgHvLWEKlXKcV2f1Ynw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, for an aggregate of twelve (12) additional months (i.e., from November 8, 2023 up to November 8, 2024) or such earlier date as determined by the Company’s board of directors. In connection with the amended Charter, on November 6, 2023, DHAC extended the period of time that it has to consummate its business combination by <span style="-sec-ix-hidden:Hidden_akA4l74ShUWPede4VJKJnQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> months from November 8, 2023 to February 8, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Furthermore, at the 2023 Annual Meeting, the stockholders of DHAC also approved an amendment to DHAC’s investment management trust agreement (the “Trust Agreement”), dated as of November 3, 2021 and as amended on October 26, 2022, by and between the Company and Continental Stock Transfer & Trust Company, which allows the Company to extend the business combination period from November 8, 2023 to up to four (4) times, each by an additional <span style="-sec-ix-hidden:Hidden_kdpkTklJxkOqxCW0FAx4wg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, for an aggregate of twelve (<span style="-sec-ix-hidden:Hidden_MOPsD2M7L0KG9qdmPM8mMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12</span></span>) additional months to November 8, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the 2023 Annual Meeting and amendments to DHAC’s Charter and Trust Agreement, 579,157 shares of Common Stock were tendered for redemption.</p>
	dhacu	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
CY2023Q3	dhacu	Transaction Costs TransactionCosts	6877164
CY2023Q3	dhacu	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	1955000
CY2023Q3	dhacu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	4370000
CY2023Q3	dhacu	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	552164
CY2023Q3	dhacu	Cash Held Outside Trust Account CashHeldOutsideTrustAccount	9478
CY2022Q4	dhacu	Number Of Extensions To Consummate Business Combination NumberOfExtensionsToConsummateBusinessCombination	3
CY2022Q4	dhacu	Extension Fee Payable By Sponsor ExtensionFeePayableBySponsor	350000
CY2022Q4	dhacu	Extension Fee Payable By Sponsor ExtensionFeePayableBySponsor	350000
	dhacu	Extension Fee For Each Additional Three Months Extension Period ExtensionFeeForEachAdditionalThreeMonthsExtensionPeriod	0
	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	10805877
	dhacu	Shares Issued And Outstanding Entitled To Vote SharesIssuedAndOutstandingEntitledToVote	4156123
	dhacu	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
	dhacu	Threshold Minimum Aggregate Fair Market Value As Percentage Of Asset Held In Trust Account ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetHeldInTrustAccount	80
	dhacu	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	50
CY2023Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10.15
CY2023Q2	dhacu	Extension Fee Payable By Sponsor ExtensionFeePayableBySponsor	350000
	dhacu	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000
	dhacu	Threshold Consecutive Trading Days Prior To Date Of Letter ThresholdConsecutiveTradingDaysPriorToDateOfLetter	P30D
CY2023Q3	dhacu	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	50000000
CY2023Q2	dhacu	Number Of Consecutive Trading Days Prior To Date Of Letter NumberOfConsecutiveTradingDaysPriorToDateOfLetter	P30D
CY2023Q2	dhacu	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	15000000
CY2023Q2	dhacu	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	15000000
CY2023Q3	dhacu	Condition For Future Business Combination Threshold Net Tangible Assets ConditionForFutureBusinessCombinationThresholdNetTangibleAssets	5000001
CY2023Q3	dhacu	Exercise Of Warrants Fractional Shares Issued ExerciseOfWarrantsFractionalSharesIssued	0
	dhacu	Amount Withdrew From Trust Account AmountWithdrewFromTrustAccount	59586
CY2023Q3	dhacu	Amount Withdrew From Trust Account AmountWithdrewFromTrustAccount	59586
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	110472254
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	507
	dhacu	Working Capital WorkingCapital	8154992
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The most significant accounting estimates were the assumptions used to fair value the PIPE Forward Contract, the Investor Note Derivative and the Bridge Note Bifurcated Derivative. Accordingly, the actual results could differ significantly from those estimates.</p>
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2022	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	10805877
CY2023Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1125
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0431
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q3	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
CY2023Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has significant cash balances at a financial institutions which throughout the year did not exceed the federally insured limited of $250,000. There was no risk of loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p>
	dhacu	Derivative Financial Instruments DerivativeFinancialInstruments	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Derivative Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as bifurcated derivatives in accordance with ASC 815. Derivative instruments are recorded at fair value on the grant date and re-valued at each reporting date, with changes in the fair value reported in the statements of operations. Derivative assets and liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Company has determined the PIPE financing agreement is a derivative instrument, the Bridge Note and the Investor Note’s early redemption provisions are embedded feature that are required to be bifurcated as a derivative. FASB ASC 470-20, “Debt with Conversion and Other Options,” addresses the allocation of proceeds from the issuance of debt into its debt and bifurcated derivative components. The Company applies this guidance to allocate the Bridge Note and the Investor Note proceeds between the Bridge Note and the Investor Note, respectively and the respective Bifurcated Derivative, using the residual method by allocating the principal first to fair value of the bifurcated derivative and then to the debt.</span></p>
CY2021Q4	dhacu	Advance From Related Party For Expenses Incurred On Behalf Of Company AdvanceFromRelatedPartyForExpensesIncurredOnBehalfOfCompany	402936
CY2023Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	138937
CY2022Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	43900
	dhacu	Proceeds Held In Trust Account Used To Repay Working Capital Loans ProceedsHeldInTrustAccountUsedToRepayWorkingCapitalLoans	0
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31650
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73850
CY2021Q4	dhacu	Maximum Number Of Demands For Registration Of Securities MaximumNumberOfDemandsForRegistrationOfSecurities	2
	dhacu	Deferred Underwriting Commission Percent DeferredUnderwritingCommissionPercent	3.8
CY2023Q3	dhacu	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
	dhacu	Months To Complete Acquisition Period MonthsToCompleteAcquisitionPeriod	P21M
	dhacu	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1
CY2023Q3	dhacu	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	12057000
CY2022Q4	dhacu	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	12057000
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
	dhacu	Warrant Exercise Period Condition One WarrantExercisePeriodConditionOne	P30D
	dhacu	Warrant Exercise Period Condition Two WarrantExercisePeriodConditionTwo	P12M
	dhacu	Number Of Warrants Exercisable For Cash NumberOfWarrantsExercisableForCash	0
	dhacu	Warrants Trading Days On Which Fair Market Value Of Shares Is Reported WarrantsTradingDaysOnWhichFairMarketValueOfSharesIsReported	5
	dhacu	Warrants Trading Days On Which Fair Market Value Of Shares Is Reported WarrantsTradingDaysOnWhichFairMarketValueOfSharesIsReported	5
CY2023Q3	dhacu	Share Price Trigger Used To Measure Dilution Of Warrants SharePriceTriggerUsedToMeasureDilutionOfWarrants	9.20
	dhacu	Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant	60
CY2023Q3	dhacu	Share Price Trigger Used To Measure Dilution Of Warrants SharePriceTriggerUsedToMeasureDilutionOfWarrants	9.20
	dhacu	Warrant Exercise Price Adjustment Multiple WarrantExercisePriceAdjustmentMultiple	115
	dhacu	Warrant Redemption Condition Minimum Share Price WarrantRedemptionConditionMinimumSharePrice	18.00
	dhacu	Warrant Redemption Price Adjustment Multiple WarrantRedemptionPriceAdjustmentMultiple	180
CY2023Q3	dhacu	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
	dhacu	Warrant Exercise Restriction Threshold Percent Of Common Stock Owned WarrantExerciseRestrictionThresholdPercentOfCommonStockOwned	9.8
CY2022Q4	dhacu	Pipe Forward Contract Derivative PipeForwardContractDerivative	170666
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0553
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0512
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y3M
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y4M17D
CY2023Q3	dhacu	Fair Value Liabilities Level1 To Level2 Transfer Amount FairValueLiabilitiesLevel1ToLevel2TransferAmount	0
CY2022Q4	dhacu	Fair Value Liabilities Level1 To Level2 Transfer Amount FairValueLiabilitiesLevel1ToLevel2TransferAmount	0

Files In Submission

Name	View Source	Status
dhacu-20230930_def.xml	Edgar Link	unprocessable
dhacu-20230930_cal.xml	Edgar Link	unprocessable
dhacu-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dhacu-20230930_lab.xml	Edgar Link	unprocessable
0001104659-23-119930-index-headers.html	Edgar Link	pending
0001104659-23-119930-index.html	Edgar Link	pending
0001104659-23-119930.txt	Edgar Link	pending
0001104659-23-119930-xbrl.zip	Edgar Link	pending
dhacu-20230930.xsd	Edgar Link	pending
dhacu-20230930x10q.htm	Edgar Link	pending
dhacu-20230930xex31d1.htm	Edgar Link	pending
dhacu-20230930xex31d2.htm	Edgar Link	pending
dhacu-20230930xex32d1.htm	Edgar Link	pending
dhacu-20230930xex32d2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
dhacu-20230930x10q_htm.xml	Edgar Link	completed
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VSEE
VSEE HEALTH, INC. Stock $vsee

2023 Q4 Form 10-Q Financial Statement

#000110465923119930 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VSEE VSEE HEALTH, INC. Stock $vsee

2023 Q4 Form 10-Q Financial Statement

#000110465923119930 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VSEE
VSEE HEALTH, INC. Stock $vsee